Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

The biotech companies PHARNEXT and BIOSYSTEMS INTERNATIONAL, the Bordeaux Hospital where CMRR is located, the university Bordeaux Segalen and Inserm (the center U897 "Epidemiology and Biostatistics") have joined forces to carry out the DIPPAL2i project. This innovative research and industrial development project is targeting Alzheimer's disease (AD) and has attracted significant financial support from OSEO (the French state innovation agency).

18 Nov 2010

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Scientists are reporting that variants of a drug already approved for treating multiple sclerosis show promise as a long sought treatment for victims of bioterrorist attack with botulinum neurotoxin which is 10,000 times deadlier than cyanide and the most poisonous substance known to man.

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

Researchers discover NG2+ cells may impact ALS disease progression

By tracking the fate of a group of immature cells that persist in the adult brain and spinal cord, Johns Hopkins researchers discovered in mice that these cells undergo dramatic changes in ALS, also known as Lou Gehrig's disease.

18 Nov 2010

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

PrecisionMed Inc. today announced at the Society for Neuroscience annual meeting in San Diego, enrollment of the first subject into the PrecisionMed Multiple Sclerosis (MS) Registry. The PrecisionMed MS Registry is a biological sample bank of DNA and serial RNA, CSF, serum and plasma associated with serial clinical testing utilizing PrecisionMed's clinical data procurement and storage capabilities.

17 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

New mechanism breaks drug resistance in ovarian cancer

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.

16 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Vit D deficiency does not raise stroke risk in African-Americans

While vitamin D deficiency is associated with fatal stroke among whites, it is not linked to more stroke deaths among blacks, according to research presented at the American Heart Association's Scientific Sessions 2010.

15 Nov 2010

Researchers improvise fruit fly as a model system to study brain development, disorders

VIB researchers attached to the K.U.Leuven have improved the fruit fly as a model for studying the connections between brain cells. The researchers developed a specific marker for a part of the fly's nerve cell which had previously been difficult to distinguish. Their discovery will not only contribute to gaining a better insight into brain development but also makes the fruit fly into a better model system for studying brain development and brain disorders.

15 Nov 2010

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

GPR124 protein controls growth of blood vessels into brains

One protein single-handedly controls the growth of blood vessels into the developing brains of mice embryos, according to researchers at the Stanford University School of Medicine. Understanding how the protein, a cellular receptor, functions could help clinicians battle brain tumors and stroke by choking off or supplementing vital blood-vessel development, and may enhance the delivery of drugs across the blood-brain barrier.

12 Nov 2010

Hospital for Special Surgery presents advantages of specialized disease center for comprehensive lupus care

The benefits of collaborative, multidisciplinary care of patients with complex autoimmune diseases like lupus and multiple sclerosis are just beginning to be appreciated by physicians. Hospital for Special Surgery in New York will present evidence of the advantages of such a specialized disease center dedicated to comprehensive lupus care at the 74th Annual Meeting of the American College of Rheumatology in Atlanta.

11 Nov 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

11 Nov 2010

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI).

11 Nov 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

New findings show promising treatment for MS

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Researchers discover NG2+ cells may impact ALS disease progression

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

New mechanism breaks drug resistance in ovarian cancer

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Adeona third quarter total net revenues increase to $289,898

Vit D deficiency does not raise stroke risk in African-Americans

Researchers improvise fruit fly as a model system to study brain development, disorders

IBEC researchers discover new group of interacting partners for myelin-associated receptors

GPR124 protein controls growth of blood vessels into brains

Hospital for Special Surgery presents advantages of specialized disease center for comprehensive lupus care

Researchers identify molecular cascade that drives sprouting in brain after stroke

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in